Diane OK means return to French market, as OC safety review continues
This article was originally published in Scrip
Executive Summary
Now that the European Commission has confirmed that Bayer's acne product, Diane (cyproterone acetate plus ethinylestradiol), should remain on the market but under strict prescribing conditions, attention will be turning to the fate of the combined hormonal contraceptives, which are also under scrutiny for their potential to cause thrombotic events.